Liu X., Ding C., Tan W.*, Zhang A.* Medulloblastoma: “molecular understanding, treatment evolution, and new developments.” Pharmacol Ther. 2020, in press (10.1016/j.pharmthera. 2020.107516).
 Wang D., Wen X., Xiong C., Zhao J., Ding C., Meng Q., Zhou H., Wang C., Uchiyama M., Lu X.*, Zhang A.* “Non-transition metal-mediated diverse aryl-heteroatom bond formation of arylammonium salts.” iScience 2019,15, 307-315.
 Ding C., Chen H., Liang B., Jiao M., Liang G.*, Zhang A.* “Biomimetic synthesis of the natural product salviadione and its hybrids: discovery of tissue-specific anti-inflammatory agents for acute lung injury.” Chem. Sci. 2019, 10, 4667-4672.
 Xue Y., Song P., Song Z., Wang A., Tong L., Geng M., Ding J., Liu Q., Sun L.*, Xie H.*, Zhang A.* “Discovery of 4,7-diamino-5-(4-phenoxyphenyl) -6-methylene-pyrimido[5,4-b]pyrrolizines as novel Bruton's tyrosine kinase (BTK) inhibitors.” J. Med. Chem. 2018, 61, 4608-4627.
 Wang D., Yang Z., Wang C.*, Zhang A.*, Uchiyama M.* “From aniline to aryl ether: a facile, efficient and versatile synthetic protocol employing mild conditions.” Angew Chem. Int. Ed. 2018, 57, 3641-3645.
 Ding C., Tian Q., Li J., Jiao M., Song S., Wang Y.*, Miao Z.*, Zhang A.* “Structural modification of natural product tanshinone I leading to discovery of novel nitrogen-enriched derivatives with enhanced anticancer profile and improved drug-like properties.” J. Med. Chem. 2018, 61, 760-776.
 Liu G., Yang J., Wang J., Liu X., Huang W., Geng, Y., Tan W.*, Zhang A.* “Discovery of novel macrocyclic hedgehog pathway inhibitors acting by suppressing the Gli-mediated transcription.” J. Med. Chem. 2017, 60, 8218-8245.
 Liu G., Xue D., Yang J., Wang J., Liu X., Huang W., Li J., Long Y.*, Tan W.*, Zhang A.* “Design, synthesis and pharmacological evaluation of 2-(2,5-dimethyl- 5,6,7,8-tetrahydroquinolin -8-yl)-N-aryl propanamides as novel smoothened (Smo) antagonists.” J. Med. Chem. 2016, 59, 11050-11068.
 Wang Y., Wang P., Wang Y., Yang G., Zhang A.*, Miao Z.* “An update on poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors: opportunities and challenges in cancer therapy.” J. Med. Chem. 2016, 59, 9575-9598.
 Fan Z., Ni J., Zhang A.* “Meta-selective CAr-H nitration of arenes through a Ru3(CO)12-catalyzed ortho-metalation strategy.” J. Am. Chem. Soc. 2016, 138, 8470-8475.
 Wang M., Shen A., Zhang C., Song Z., Ai J., Liu H., Sun L.*, Ding J., Geng M.*, Zhang A.* “Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through Hsp90-kinase interactions.” J. Med. Chem. 2016, 59, 5563-5586.
 Fan Z., Shu S., Ni J., Yao Q., Zhang A.* “Ligand-promoted Pd(II)-catalyzed functionalization of unactivated C(sp3)−H bond: regio- and stereoselective synthesis of arylated rimantadine derivatives.” ACS Catalysis, 2016, 6, 769-774.
 Wei M., Wang X., Song Z., Jiao M., Ding J., Meng L.*, Zhang A.* “Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.” Med. Res. Rev. 2015, 35,720-752.
 Song Z., Yang Y., Liu Z., Peng X., Guo J., Yang X., Wu K., Ai J.*, Ding J., Geng M.*, Zhang A.* “Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.” J. Med. Chem. 2015, 58, 197-211.
 Ye N., Neumeyer J. L., Baldessarini R. J., Zhen X., Zhang A.* “Recent progress in the development of dopamine receptor subtype compounds: potential therapeutic agents for neurological and neuropsychiatric disorders.” Chem. Rev. 2013, 113, PR123-PR178.
 Ye N., Chen C., Chen T., Song Z., He J., Huan X., Song S., Liu Q., Chen Y., Ding J., Xu Y.*, Miao Z.*, Zhang A.* “Design, synthesis and biological evaluation of a series of benzo[de][1,7] naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors.” J. Med. Chem. 2013, 56, 2885-2903.
 Zhang H., Ye N., Zhou S., Guo L., Zheng L., Liu Z., Gao B., Zhen X.*, Zhang A.* “Identification of N-propylnoraporphin-11-yl 5-(1,2-Dithiolan-3-yl)pentanoate as a new anti-parkinson's agent possessing a dopamine D2 and serotonin 5-HT1A dual-agonist profile.” J. Med. Chem. 2011, 54, 4324-4338.
 Wang Y., Ai J., Wang Y., Chen Y., Wang L., Liu G., Geng M.*, Zhang A.* “Synthesis and c-Met kinase inhibition of 3,5-di- and 3,5,7-tri- substituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)- 5-(3-nitrobenzylamino)- 7- (trifluoromethyl)quinoline as a novel anticancer agent.” J. Med. Chem. 2011, 54, 2127-2142.